BiotechTube
Alzheon

Alzheon

Framingham, United States· Est.
alzheon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $355.2M

Overview

Alzheon is a private, clinical-stage biotech advancing a late-stage, oral therapy for Alzheimer's disease. Its lead candidate, valiltramiprosate (ALZ-801), has completed a pivotal Phase 3 trial (APOLLOE4) targeting high-risk APOE4/4 homozygous patients, with data published in 2025. The company's strategy is based on a precision medicine platform focused on inhibiting neurotoxic soluble amyloid oligomers, a key driver of pathology, and it has been supported by significant non-dilutive funding from the National Institute on Aging.

Alzheimer's DiseaseNeurodegenerative Disorders

Technology Platform

Precision medicine platform focused on inhibiting neurotoxic soluble amyloid oligomers, the primary drivers of protein misfolding and aggregation in Alzheimer's disease. Utilizes an oral prodrug approach to target and neutralize these toxic species.

Funding History

13
Total raised:$355.2M
Grant$2.3M
Series D$100M
Grant$425K
Grant$6.5M

Opportunities

The oral administration of valiltramiprosate offers a major convenience and accessibility advantage over current injectable Alzheimer's therapies, potentially improving patient compliance and expanding treatment reach.
The precision medicine focus on the high-risk APOE4/4 population provides a clear regulatory pathway and addresses a severe unmet need with a motivated patient base.

Risk Factors

The company faces significant regulatory risk as it prepares for FDA review of its Phase 3 data, and commercial risk from intense competition with well-funded developers of anti-amyloid antibodies.
As a private, pre-revenue company, Alzheon also carries financial risk, requiring additional capital to fund regulatory submissions and commercialization efforts.

Competitive Landscape

Alzheon competes in the rapidly evolving Alzheimer's disease-modifying therapy market, dominated by anti-amyloid monoclonal antibodies like Eisai/Biogen's lecanemab and Eli Lilly's donanemab. Its primary competitive differentiation is the oral route of administration and a targeted safety profile aimed at reducing the risk of ARIA (amyloid-related imaging abnormalities), a class-side effect of antibody therapies.

More companies in Neuroscience & CNS →More companies in United States →